Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
暂无分享,去创建一个
M. Linton | T. Gebretsadik | C. Stein | C. Chung | A. Shintani | S. Fazio | A. Oeser | J. Solus | I. Avalos | Ingrid Avalos
[1] S. Bandinelli,et al. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. , 2007, Atherosclerosis.
[2] P. Raggi,et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors , 2006, Annals of the rheumatic diseases.
[3] P. Raggi,et al. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus , 2006, Lupus.
[4] K. Kalunian,et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[5] C. Greenwood,et al. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.
[6] E. Bonfá,et al. Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus , 2006, Clinical & developmental immunology.
[7] A. Drosos,et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study , 2006, Arthritis research & therapy.
[8] P. Raggi,et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. , 2006, The Journal of rheumatology.
[9] D. Borderie,et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[10] O. Johnson,et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy , 2006, Scandinavian journal of rheumatology.
[11] I. Bruce,et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. , 2006, Journal of Rheumatology.
[12] M. H. Ahmed. Chloroquine-induced nitric oxide improves insulin sensitivity in rheumatoid arthritis. , 2006, Medical hypotheses.
[13] P. Raggi,et al. Endothelial Function in Systemic Lupus Erythematosus: Relationship to Disease Activity, Cardiovascular Risk Factors, Corticosteroid Therapy, and Coronary Calcification , 2005, Vascular health and risk management.
[14] C. Stein,et al. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.
[15] B. Dijkmans,et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.
[16] Eduardo Esteve,et al. Dyslipidemia and inflammation: an evolutionary conserved mechanism. , 2005, Clinical nutrition.
[17] J. Ramires,et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. , 2004, Atherosclerosis.
[18] E. Borba,et al. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? , 2004, Arthritis and rheumatism.
[19] M. Reilly,et al. Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary Atherosclerosis , 2004, Circulation.
[20] J. Fruchart,et al. Atherogenic Lipoprotein Particles in Atherosclerosis , 2004, Circulation.
[21] Paolo Raggi,et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.
[22] J. Schwartz,et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.
[23] L. Klareskog,et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. , 2003, Arthritis and rheumatism.
[24] B. Joffe,et al. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. , 2003, The Journal of rheumatology.
[25] G. Hughes,et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. , 2003, Journal of lipid research.
[26] M. Reichlin,et al. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.
[27] K. Matthews,et al. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. , 2002, The American journal of cardiology.
[28] F. Formiga,et al. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients , 2001, Lupus.
[29] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[30] K. Feingold,et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.
[31] J. Ramires,et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.
[32] I. Bruce,et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. , 1999, The Journal of rheumatology.
[33] M. Ward. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.
[34] J. L. Carrillo,et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. , 1998, Clinica chimica acta; international journal of clinical chemistry.
[35] H. Lithell,et al. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[36] E. Bonfá,et al. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies , 1997, Lupus.
[37] D. Gladman,et al. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. , 1997, The Journal of rheumatology.
[38] H. Krumholz,et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. , 1997, Circulation.
[39] R. D'Agostino,et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.
[40] W. Emlen,et al. Serum and urinary interleukin-6 in systemic lupus erythematosus , 1996, Lupus.
[41] D. Symmons,et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.
[42] D. Gladman,et al. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. , 1995, The Journal of rheumatology.
[43] E. Harris,et al. The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.
[44] K. Feingold,et al. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. , 1994, Lymphokine and cytokine research.
[45] B. Ryffel,et al. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. , 1994, The American journal of pathology.
[46] L. Magder,et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. , 1994, The American journal of medicine.
[47] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[48] L. Wide,et al. Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. , 1987, Metabolism: clinical and experimental.
[49] A. Goldberg,et al. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. , 1987, The American journal of medicine.
[50] W. Kannel,et al. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.
[51] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.